Document is current

Article History

Received: 28 May 2025

Accepted: 6 August 2025

First Online: 28 August 2025

Declarations

:

: As in this study no data was used that could be referred to individual human or animal subjects, no ethical approval is required.

: Financial interests: O.O.has received speaker honorarium from AstraZeneca; Astellas Pharma; Novartis Pharma; and ownes stocks of Novartis, Bayer, Fresenius Medical Care, Curevac. R.R.: Employee of the German Cancer Society. B.K.: Employee of the German Cancer Society. C.K.: Employee of the German Cancer Society. J.B.: Employee of the German Cancer Society. P.W. has received research funding for institution from Amgen, abbvie, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly, honoraria from Amgen, abbvie, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, Daichii Sankyo. PW participates at advisory boards from Amgen, abbvie, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead and Daichii Sankyo. J.S. reports receiving research funding, consultancy/advisory board fees, honoraria, travel and accommodation fees, and expenses from AstraZeneca, Bayer AG, Bristol Myers Squibb, Clovis Oncology, Corcept Therapeutics, Eisai Co, Gilead Sciences, GlaxoSmithKline, Ingress Health, Janssen-Cilag GmbH (Johnson & Johnson), Karyopharm Therapeutics, Eli Lilly and Company, Merck KGaA, MSD Oncology, Myriad Genetics, Novartis International AG, Novocure GmbH, Olympus Medical Systems Corp, Pfizer Inc, PharmaMar, Roche Holding AG, Swedish Orphan Biovitrum AB (Sobi), Teva Pharmaceutical Industries. M.W.B. has no relevant financial interests to disclose. S.S.-T.: SST received speaker honorarium from Pfizer, Roche and author honorarium from thieme and further training was supported by GSK and Celgene. Non-financial interests: O.O., P.W., J.S., M.W.B. and S.S.-T. work at high-volume gynecological cancer centers with >30 primary surgical ovarian cancer cases per year. O.O.: Memberships: Member of the Board of the German Cancer Society, Board of Trustees of German Cancer Aid, Member of the Board of ADT; Memberships of professional associations: German Society for Gynecology and Obstetrics - Gynecological Oncology Working Group, Kommission OVAR; German Society for Senology; German Society for Endocrinology; Working Group for Gynecologic Oncology; German Cancer Society; Bavarian Cancer Society; Bavarian Society for Obstetrics and Gynecology; Coordinator of the S3 guideline “Peri- and Postmenopause - Diagnostics and Interventions”; Mandate holder for the DKG Certification Commission for Gynecological Cancer Centers. R.R.: None. B.K.: None. C.K.: None. J.B.: Member of the Board of the German Cancer Society. P.W.: Member of the German Society for Gynecology and Obstetrics (DGGG); Speaker of the Working Group for Gynecologic Oncology (AGO) and the Kommission OVAR and Member of the German Cancer Society (DKG), Member of ESGO and ASCO. Coordinator of the S3 Guideline for ovarian cancer. Member of the S3 Guideline for cervical cancer and prevention. Member of the European (ESGO) guideline for endometrial cancer. J.S.: Founding member and board member of the North-Eastern German Society for Gynaecological Oncology (NOGGO); Founding member and board member of the German Ovarian Cancer Foundation; Member of the Working Group for Gynecologic Oncology (AGO) and the Kommission OVAR; Member of the German Cancer Society (DKG); President Elect of the European Society of Gynaecological Oncology (ESGO); Member of Gynaecologic Cancer Intergroup (GCIG); Member of American Society of Clinical Oncology (ASCO); Member of the German Society for Gynecology and Obstetrics (DGGG); Member of the Ovarian Cancer Consensus Conference Committee (OCCC); Member of the Society of Pelvic Surgeons. M.W.B. has no relevant non-financial interests to disclose. S.S.-T.: SST is Member of the Working Group for Cervical Pathology and Colposcopy (AG-CPC); Member of the German Society for Gynecology and Obstetrics (DGGG); Member of the Working Group for Gynecologic Oncology (AGO) and the Kommission OVAR and Member of the German Cancer Society (DKG).